期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肾细胞癌组织与正常组织中VEGF165b的差异表达及其意义 被引量：2

The differential expression of VEGF165b in the renal cell carcinoma and normal renal tissues and its clinical significance
下载PDF
导出
摘要 目的:研究血管内皮生长因子165b(Vascular endothelial growth factor 165b,VEGF165b)在肾细胞癌(Renalcellcarcino-ma,RCC)组织和正常组织中的表达情况,初步探讨其与肾细胞癌发生发展的关系。方法:(1)用S-P免疫组化法检测30例肾细胞癌组织和29例正常肾组织中VEGF165b蛋白的表达情况;(2)用RT-PCR法分别检测32例肾细胞癌组织和30例正常肾组织中VEGF165b mRNA的表达情况。结果:(1)正常肾组织中VEGF165b蛋白表达率为96.55%(28/29),肾细胞癌组织中VEGF165b蛋白的表达率为20.00%(6/30),表达差异有统计学意义(P<0.05)。(2)正常肾组织中VEGF165b mRNA阳性表达率为93.33%(28/30),肾细胞癌组织中VEGF165b mRNA的阳性表达率为18.75%(6/32),具有统计学意义(P<0.05)。结论:VEGF165b在肾细胞癌组织中的表达低于正常肾组织的表达,这种表达差异可能与肾癌发生、发展的机制有关。 Objective： To investigate the differential expression of VEGF165b in the renal cell carcinoma （RCC） and normal renal tissues and its role in the development of RCC. Methods： S-P immunohistochemistry was used to detect the expression of VEGF165b protein in 30 specimens of paraffin-embedded RCC tissues and 29 specimens of paraffin-embedded normal renal tissues. RT-PCR was performed to detect the expression of VEGF165b mRNA in 32 specimens of fresh RCC tissues and 30 specimens of fresh normal renal tissues. Results： Among 29 of normal renal tissues, 28 specimens had positive expression of VEGF165b protein, with the positive rate of 96.55% （28/29） that was significantly higher than 20.00% （6/30）in RCC tissues （P〈0.05）. The positive rate of VEGF165b mRNA in normal renal tissues was 93.33%（28/30） ,while that of RCC tissues was only 18.75% （6/32）. The positive expression rate of VEGFI65b mRNA in RCC tissues was significantly lower than that in normal renal tissues （P〈0.05）. Conclusion： VEGF165b might play a role in inhibiting development of RCC. Vascular endothelial growth factor 165b.
作者 姜翠苹 王德林 彭波
机构地区 重庆医科大学附属第一医院泌尿外科
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2009年第3期281-284,共4页 Journal of Chongqing Medical University
基金 重庆市自然科学基金资助项目(CSTC2005BB5033)
关键词 肾肿瘤 VEGF165B 免疫组织化学 逆转录-聚合酶链反应(RT—PCR) Kidney neoplasms Vascular endothelial growth factor 165b Immunohistochemistry Reverse transcriptasc polymerase chain reaction （RT-PCR）
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1吴小候,罗春丽,蔡晓钟.膀胱移行细胞癌尿脱落细胞VEGF表达的研究[J].重庆医科大学学报,2002,27(1):45-47. 被引量：2
  • 2张尧,吴小候,孙先禹,何俊,曾定胜,康川疆.肾细胞癌MMP-9、VEGF的表达及其临床意义[J].重庆医学,2007,36(13):1298-1300. 被引量：6
  • 3Canneliet P. Angiogenesis in life, disease and medicine[J]. Nature, 2005,438 (7070): 932-936.
  • 4Siemann D W, Chaplin D J, Horsman M R. Vascular-targeting therapies for treatment of malignant disease[J]. Cancer, 2004, 100 (12): 2491-2499.
  • 5Bates D O,Cui T G,Doughty J M,et al. VEGF165b,an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma[J]. Cancer Res, 2002,62:4123-4131.
  • 6Ohnami S, Matsumoto N, Nakano M,et al. Identification of genes showing diferential expression in antisense k-ras-transduced pancreatic cancer cells with suppressed tumorigenicity[J]. Cancer Res, 1999,59: 5565-5571.
  • 7Konopatskaya O, Churchill A J, Harper S J, et al. VEGF165b,an endogenous C-terminal splice variant of VEGF inhibits retinal neovascularization in mice[J]. Molecular Vision, 2006,12: 626-632.
  • 8Woolard J,Wang W Y,Bevan H S,et al. VEGF165b,an inhibitory vascular endothelial growth factor splice variant: mechanism of action,in vivo effect on angiogenesis and endogenous protein expression[J]. Cancer Res, 2004,64: 7822-7835.
  • 9Glass C A, Harper S J, Bates D O. The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity,probably through VEGF receptor 1 in vivo[J]. J Physiol, 2006,572: 243-257.
  • 10Varey A H R,Rennel E S,Qiu Y,et al. VEGF165b,an antiangiogenic VEGF-A isoform,binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy[J]. Br J Cancer, 2008,98: 1366-1379.

二级参考文献17

  • 1[1]Crew JP.Vascular endothelial growth factor an important angiogenic in bladder cancer[J].Eur Uro1,1999;35(1):2-8.
  • 2[2]Ferrara N,and Davis-Smyth TD.The biology of vascular endothelial growth factor[J].Endocr .Rev,1997;10(4):4-9.
  • 3[3]OBrien T.Cranston D .Fuggle S,et al.Different angiogenic pathways characterize superficial and invasive bladder cancer[J].Cancer Res,1995;55(5):510-513.
  • 4[4]Ogura Y,Sato K,Karo T,et al.Immunohistochemical analysis of expression of angiogenic factors and tumour angiogenesis in superficial bladder canaer[J].Nippon Hinyokika Gakkai Zasshi,1998;89(5):529-537.
  • 5[5]Jones A and Crew JP.Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrent rates and progression[J].Urol Clin North Am,2000;27(1): 191-196.
  • 6[6]Crew JP,OBrien T,Bicknell R,et al.Urinary Vascular endothelial growth factor and its correlation with bladder cancer recurrent rates[J].J Urol,1999;161 (3):799-804.
  • 7Senger DR,Ledbetter SR,Claffey KP,et al.Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor though cooperative mechanism involving the αvβ3 integrin[J].Am J Pathol,1996,149:293.
  • 8Rooprai HK,Rucklidge GJ,Panou C,et al.The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumor[J].Br J Cancer,2000,82(1):52.
  • 9Gabriele B,Rolf B,Gerald M,et al.Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis[J].Nature Cell Biol,2000,2(10):737.
  • 10Shimizu M,Saith Y,Jtoh H,et al.Immunohistochemical staining of Ha-ras oncogene product in normal benign and malignant human pancreatic tissues[J].Hum Pathol,1990,21:607.

共引文献6

同被引文献25

  • 1Moeh H.Cystic renal tumors:new entities and novelcon- eepts[J].Adv Anat Pathol,2010,17(3) :209-214.
  • 2Vikram R, Ng CS,Tamboli P,et al.Papillary renal cell car- cinoma:radiologic-pathologic correlation and spectrum of disease[J]. Radiographics, 2009,29 (3) : 741-754.
  • 3Evelyhe D,Patricia H,Ande V,et al.Tumor angiogenesis and tissuefactor expression during hepatocellular carcono- ma progression in a transgenic mouse model[J].J Hepatol, 2003,38(6) :793-802.
  • 4Basu A, Banerjee P, Contreras AG,et al.Calcineurin in- hibitor-induced and Rasmediated overexpression of VEGF in renal cancer ceils involves mTOR through the regula- tion of PRAS40[J].PLoS One,2011,6(8) :e23919.
  • 5Nomiya T, Nemoto K, Nakata E,et al.Expression" of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma[J].Oncol Rep,2006,15(6) : 1497-501.
  • 6Rennel E,Waine E, Guanh H,et al.The endogenous anti- angiogenie VEGF isoform,VEGF165b inhibits human tu- mour growth in mice[J].Br J Cancer,2008,98 (7):1250- 1257.
  • 7Konopatskaya O, Churchill A J, Harper SJ, et al.VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice[J].Molecular Vision,2006, 12 : 626-632.
  • 8Cui TG,Foster RR,Saleem M,et al.Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein[J].Am J Physiul Renal Physiol,2004,286(4):F767- 773.
  • 9Woolard J, Bevan HS, Harper SJ,et al.Molecular diversity of VEGF-A as a regulator of its biological activity[J].Microeirculation, 2009,16(7) : 572-592.
  • 10Siemann DW,Chaplin DJ,Horsman MR.Vascular-target- ing therapies fortreatment ofmalignant disease[J].Cancer, 2004,100 (12) : 2491-2499.

引证文献2

二级引证文献5

重庆医科大学学报
2009年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部